id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-4589-0008,FDA,FDA-2016-E-4589,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2025-11-24T05:00:00Z,2025,11,2025-11-24T05:00:00Z,,2025-11-25T03:04:10Z,,0,0,09000064b909515b
FDA-2016-E-4589-0007,FDA,FDA-2016-E-4589,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2025-09-19T04:00:00Z,2025,9,2025-09-19T04:00:00Z,,2025-09-19T20:44:37Z,,0,0,09000064b8fb490e
FDA-2016-E-4589-0006,FDA,FDA-2016-E-4589,Determination of Regulatory Review Period for Purposes of Patent Extension; XTAMPZA ER,Notice,Determinations,2024-12-30T05:00:00Z,2024,12,2024-12-30T05:00:00Z,2025-03-01T04:59:59Z,2024-12-30T17:05:09Z,2024-31023,0,0,0900006486894e08
FDA-2016-E-4589-0005,FDA,FDA-2016-E-4589,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2024-12-19T05:00:00Z,2024,12,2024-12-19T05:00:00Z,,2024-12-19T13:28:28Z,,0,0,090000648687e04c
FDA-2016-E-4589-0004,FDA,FDA-2016-E-4589,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-03-22T04:00:00Z,2024,3,2024-03-22T04:00:00Z,,2024-03-22T18:17:26Z,,0,0,090000648648d31c
FDA-2016-E-4589-0003,FDA,FDA-2016-E-4589,Letter to U S Patent and Trademark Office,Other,Letter(s),2023-10-20T04:00:00Z,2023,10,2023-10-20T04:00:00Z,,2025-11-01T00:49:18Z,,0,0,09000064861135ef
FDA-2016-E-4589-0001,FDA,FDA-2016-E-4589,"Patent Extension Application from Cooley LLP (on behalf of Collegium Pharmaceutical, Inc)",Other,Application,2016-12-28T05:00:00Z,2016,12,2016-12-28T05:00:00Z,,2016-12-28T17:56:06Z,,0,0,090000648243b75c
FDA-2016-E-4589-0002,FDA,FDA-2016-E-4589,Letter from U.S. Patent and Trademark Office to CDER,Other,Letter(s),2016-12-28T05:00:00Z,2016,12,2016-12-28T05:00:00Z,,2016-12-28T18:00:41Z,,0,0,090000648243b3fe